Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC? - authors' reply

Affiliations

¹ The Chinese University of Hong Kong, Sir YK Pau Cancer Center, State Key Laboratory of Southern China, Prince of Wales Hospital, Hong Kong, China. Electronic address: tony@clo.cuhk.edu.hk.
² Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong, China.

Comment

Tony S K Mok et al. Lancet Oncol. 2013 Oct.

. 2013 Oct;14(11):e438-e439.

doi: 10.1016/S1470-2045(13)70434-0.

¹ The Chinese University of Hong Kong, Sir YK Pau Cancer Center, State Key Laboratory of Southern China, Prince of Wales Hospital, Hong Kong, China. Electronic address: tony@clo.cuhk.edu.hk.
² Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong, China.

No abstract available

Comment on

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, Sun Y, Margono B, Fuerte F, Chang GC, Seetalarom K, Wang J, Cheng A, Syahruddin E, Qian X, Ho J, Kurnianda J, Liu HE, Jin K, Truman M, Bara I, Mok T. Wu YL, et al. Lancet Oncol. 2013 Jul;14(8):777-86. doi: 10.1016/S1470-2045(13)70254-7. Epub 2013 Jun 17. Lancet Oncol. 2013. PMID: 23782814 Clinical Trial.
Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC?
Zheng Y, Xu N, Zhou J. Zheng Y, et al. Lancet Oncol. 2013 Oct;14(11):e438. doi: 10.1016/S1470-2045(13)70412-1. Lancet Oncol. 2013. PMID: 24079869 No abstract available.